May 12, 2020 / 11:45 AM / 15 days ago

BRIEF-Black Diamond Therapeutics Reports Qtrly Loss Per Share Of $0.51

May 12 (Reuters) - Black Diamond Therapeutics Inc:

* BLACK DIAMOND THERAPEUTICS - QTRLY LOSS PER SHARE $0.51

* BLACK DIAMOND THERAPEUTICS - CASH, CASH EQUIVALENTS OF $357.2 MILLION AS OF MARCH 31, 2020, BELIEVED TO BE SUFFICIENT TO FUND OPERATIONS INTO 2023

* BLACK DIAMOND THERAPEUTICS - WELL POSITIONED TO EXECUTE ON CLINICAL DEVELOPMENT OF BDTX-189 AS PLANNED

* BLACK DIAMOND THERAPEUTICS - CONTINUED TO ENROLL, DOSE PATIENTS IN PHASE 1 PORTION OF PHASE 1/2 CLINICAL TRIAL OF BTDX-189

* BLACK DIAMOND THERAPEUTICS - EXPECTS TO COMPLETE PHASE 1 PORTION OF PHASE 1/2 CLINICAL TRIAL OF BTDX-189 BY H1 2021 Source text: bit.ly/2WPw1OQ Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below